The development of β-adrenergic receptor antagonists for the treatment of heart failure: A paradigm for translational science

Circulation Research

Volumn 109, Issue 10, 2011, Pages 1173-1175

  Feldman, Arthur M ^a  

^a NONE

Author keywords

adrenergic receptor antagonists; heart failure; translational medicine

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; NEBIVOLOL;

HEART FAILURE; HEART MUSCLE; HUMAN; PRIORITY JOURNAL; REVIEW; TRANSLATIONAL RESEARCH;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CARDIOVASCULAR AGENTS; DRUG DISCOVERY; HEART FAILURE; HUMANS; MYOCARDIUM; RECEPTORS, ADRENERGIC, BETA; TRANSLATIONAL MEDICAL RESEARCH;

EID: 80155214423     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.111.255976     Document Type: Review

References (26)

1. Collins FS. Genome-sequencing anniversary. Faces of the genome. Science. 2011;331:546.
2. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, Strobeck JE, Hendrix GH, Powers ER, Bain RP, White BG, for the Vesnarinone Study Group. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone study group. New Engl J Med. 1993;329:149-155. (Pubitemid 23195734)
3. Bozkurt B, Torre-Amione G, Warren MS, Whitmore J, Soran OZ, Feldman AM, Mann DL. Results of targeted anti-tumor necrosis factor therapy with etanercept (Enbrel) in patients with advanced heart failure. Circulation. 2001;103:1044-1047. (Pubitemid 32200174)
4. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Fleming T. Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (renewal). Circulation. 2004;109:1594-1602. (Pubitemid 38451714)
5. Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, Gottlieb SO, McGrew F III, DeMets DL, White BG. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone trial investigators. New Engl J Med. 1998;339: 1810-1816. (Pubitemid 29005785)
6. Bristow MR. Treatment of chronic heart failure with beta-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology. Circ Res. 2011;109:1176-1194.
7. Chidsey CA, Harrison DC, Braunwald E. Augmentation of the plasma nor-epinephrine response to exercise in patients with congestive heart failure. New EnglJ Med. 1962;267:650-654.
8. Chidsey CA, Sonnenblick EH, Morrow AG, Braunwald E. Norepinephrine stores and contractile force of papillary muscle from the failing human heart. Circulation. 1966;33:43-51.
9. Stanton HC, Brenner G, Mayfield ED Jr. Studies on isoproterenolinduced cardiomegaly in rats. Am Heart J. 1969;77:72-80.
10. Mann DL, Kent RL, Parsons B, Cooper Gt. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation. 1992;85: 790-804.
11. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P, Jamieson S, Stinson EB. Beta 1-and beta 2-adrenergic- receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res. 1986;59:297-309. (Pubitemid 17178124)
12. Zhu WZ, Wang SQ, Chakir K, Yang D, Zhang T, Brown JH, Devic E, Kobilka BK, Cheng H, Xiao RP. Linkage of beta1-adrenergic stimulation to apoptotic heart cell death through protein kinase a-independent activation of ca2f/calmodulin kinase ii. J Clin Inves. 2003;111:617-625. (Pubitemid 36278580)
13. Roth DM, Lai NC, Gao MH, Drumm JD, Jimenez J, Feramisco JR, Hammond HK. Indirect intracoronary delivery of adenovirus encoding adenylyl cyclase increases left ventricular contractile function in mice. Am J Physiol Heart Circ Physiol. 2004;287:H172-H177. (Pubitemid 38802350)
14. Koch WJ, Rockman HA, Samama P, Hamilton RA, Bond RA, Milano CA, Lefkowitz RJ. Cardiac function in mice overexpressing the betaadrenergic receptor kinase or a beta ark inhibitor. Science. 1995;268: 1350-1353.
15. Lymperopoulos A, Rengo G, Funakoshi H, Eckhart AD, Koch WJ. Adrenal grk2 upregulation mediates sympathetic overdrive in heart failure. Nat Med. 2007;13:315-323. (Pubitemid 46376685)
16. Noma T, Lemaire A, Naga Prasad SV, Barki-Harrington L, Tilley DG, Chen J, Le Corvoisier P, Violin JD, Wei H, Lefkowitz RJ, Rockman HA. Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the egfr confers cardioprotection. JClin Inves. 2007;117:2445-2458.
17. Bueno OF, Molkentin JD. Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circulation research. 2002;91:776-781. (Pubitemid 35285074)
18. Bisognano JD, Weinberger HD, Bohlmeyer TJ, Pende A, Raynolds MV, Sastravaha A, Roden R, Asano K, Blaxall BC, Wu SC, Communal C, Singh K, Colucci W, Bristow MR, Port DJ. Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. J Molec Cell Cardiol. 2000;32:817-830. (Pubitemid 30658918)
19. Freeman K, Lerman I, Kranias EG, Bohlmeyer T, Bristow MR, Lefkowitz RJ, Iaccarino G, Koch WJ, Leinwand LA. Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J Clin Inves. 2001;107:967-974. (Pubitemid 32323407)
20. Ikram H, Fitzpatrick D. Double-blind trial of chronic oral beta blockade in congestive cardiomyopathy. Lancet. 1981;2:490-493. (Pubitemid 11051464)
21. Bristow MR. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. Am J Cardiol. 1993;71:12C-22C. (Pubitemid 23092238)
22. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D, Cody RJ, Gregory JJ, Kantrowitz NE, LeJemtel TH, Young ST, Lukas MA, Shusterman NH. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The precise trial. Prospective randomized evaluation of carvedilol on symptoms and exercise. Circulation. 1996;94:2793-2799. (Pubitemid 26411743)
23. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Mocha investigators. Circulation. 1996;94:2807-2816. (Pubitemid 26411745)
24. Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Larrabee P, Ferguson D, Wolfel EE, Lindenfeld J, Tsvetkova T, Robertson AD, Quaife RA, Bristow MR. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. New Engl J Med. 2002;346: 1357-1365. (Pubitemid 34754608)
25. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, Hodne D, Nelson B, Morrison J, Domanski MJ, Wagoner LE, Abraham WT, Anderson JL, Carlquist JF, Krause-Steinrauf HJ, Lazzeroni LC, Port JD, Lavori PW, Bristow MR. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci USA. 2006;103:11288-11293. (Pubitemid 44156511)
26. Patel PA, Tilley DG, Rockman HA. Physiologic and cardiac roles of beta-arrestins. J Mol Cell Cardiol. 2009;46:300-308.